234 related articles for article (PubMed ID: 21844709)
1. Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia.
Pereira AM
Curr Opin Endocrinol Diabetes Obes; 2011 Aug; 18(4):264-8. PubMed ID: 21844709
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.
Dekkers OM; Lagro J; Burman P; Jørgensen JO; Romijn JA; Pereira AM
J Clin Endocrinol Metab; 2010 Jan; 95(1):43-51. PubMed ID: 19880787
[TBL] [Abstract][Full Text] [Related]
3. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
4. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.
Xia MY; Lou XH; Lin SJ; Wu ZB
Endocrine; 2018 Jan; 59(1):50-61. PubMed ID: 29043560
[TBL] [Abstract][Full Text] [Related]
5. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
6. Pituitary gland: can prolactinomas be cured medically?
Molitch ME
Nat Rev Endocrinol; 2010 Apr; 6(4):186-8. PubMed ID: 20336161
[TBL] [Abstract][Full Text] [Related]
7. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
8. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline, a hopeful medicine for prolactinomas and non-tumoral hyperprolactinemia.
Miki N
Intern Med; 2001 Sep; 40(9):845-6. PubMed ID: 11579939
[No Abstract] [Full Text] [Related]
10. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
11. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
12. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
13. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis.
Zou Y; Li D; Gu J; Chen S; Wen X; Dong J; Jiang X
BMC Endocr Disord; 2021 Nov; 21(1):225. PubMed ID: 34774043
[TBL] [Abstract][Full Text] [Related]
14. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
Sosa-Eroza E; Espinosa-Cárdenas E
Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
[TBL] [Abstract][Full Text] [Related]
17. Prolactin excess: treatment and toxicity.
Gillam MP; Fideleff H; Boquete HR; Molitch ME
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
[TBL] [Abstract][Full Text] [Related]
18. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
19. Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.
Hage C; Salvatori R
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32930718
[TBL] [Abstract][Full Text] [Related]
20. Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis.
D'Sylva C; Khan T; Van Uum S; Fraser LA
Neuro Endocrinol Lett; 2015; 36(8):745-9. PubMed ID: 26921574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
